Pulnovo Medical Announces First Two U.S. Patients for PULSE-LHD IDE Clinical Trial Treatment of Pulmonary Hypertension Related to Left Cardiac Disease

On August 24, 2026, Pulnovo Medical has enrolled the first two patients in the United States FDA into its PULSE-LHD IDE investigational Device Exemption clinical trial, representing a major progress in the evaluation of pulmonary artery denervation as treatment for pulmonary hypertension connected to left heart disease. Patient enrollment in the United States comes after receipt of FDA IDE approval and sets a breakthrough for Pulnovo’s expansion of its clinical development programme into America’s infrastructure. The randomized, placebo-controlled study was intended to examine the effectiveness and patient safety of Pulnovo’s catheter-driven Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System.

The clinical trial specifically focuses on Group 2 pulmonary hypertension, promoted by WHO Group regulatory compliance for a large group of patients. This achievement accelerates Pulnovo’s standing in the field of interventional cardiology and pulmonary hypertension by influencing close attention to device-driven methods of approaching complex cardiovascular disease. If the results are successful, they could help to support future regulatory and reimbursement strategies and lead to pulmonary artery denervation as a minimally invasive treatment asset.

Impact on the Medical Devices Sector

The global medical devices market size is valued at USD 678.88 billion in 2025 and is projected to increase from USD 719.61 billion in 2026 to approximately USD 1,209.42 billion by 2035, expanding at a CAGR of 5.94% from 2026 to 2035.

According to Precedence Research, the rising chronic diseases and medical technology leads to the integration of the PULSE-LHD trial for the medical devices industry by promoting a minimally invasive method using a catheter for challenging cardiovascular situations. The trial could prompt competitors to speed up their development of other denervation technologies and catheter systems. The procedure known as pulmonary artery denervation is an emerging type of device that could supplement existing ways of managing heart failure through clinical benefits.

This transition has the potential to lead to greater opportunities for specialized manufacturers of cardiovascular devices. Positive results from the United States could support to strengthen Pulnovo's regulatory viewpoint and open up possibilities for inclusive commercialization, reimbursement, and acceptance by hospitals. Additionally, on a domestic and global scale, the study shows that interventional devices like the PULSE-LHD IDE are becoming more focused on addressing the primary physiological mechanisms rather than symptoms that are managed with conventional drug treatments.

Impact on the Pulmonary Arterial Hypertension Sector

The global pulmonary arterial hypertension market size is calculated at USD 8.48 billion in 2025 and is predicted to increase from USD 8.93 billion in 2026 to approximately USD 13.50 billion by 2034, registering a notable CAGR of 5.30% between 2025 and 2035.

According to Precedence Research, the maturation of biotechnology and rising risk of cardiovascular disorder in all age groups. This initiative of pulmonary artery denervation is found to be both safe and clinically effective; it would give doctors a new interventional choice for certain patients whose pulmonary pressures are still a problem even after they have received standard heart failure therapy. PULSE-LHD IDE aimed at meeting an important unmet requirement in the field of cardiology and the care of patients with heart failure, because pulmonary hypertension linked to left heart disease is common and has no specifically approved treatments.

This trial in the United States is especially significant in order to determine whether the procedure provides meaningful benefits over standard cardiovascular care. If the results are successful, they could affect future treatment routes, patterns of referral to specialists, and the part that catheter-based interventions will play in the management of advanced heart failure. Additionally, it might result in increased alliance between cardiologists and specialists in pulmonary hypertension associated with left heart disease.

Expert Opinion

From the point of view of the expert, the first U.S. patients enrolled in PULSE-LHD IDE is a significant clinical and commercial achievement for Pulnovo Medical. Vital factors will be the long-term outcomes, patient selection, procedural safety, and the ability to reproduce the results at different centres. This importance reaches beyond the enrollment itself as the company is attempting to determine whether pulmonary artery denervation can progress from an emerging interventional approach to a proven treatment for Group 2 pulmonary hypertension.

In my opinion, the clinical trial is of strategic value because it has the potential to establish a new device-based treatment option for cardiovascular patients who have substantial unmet medical necessities. If the trial produces positive results, Pulnovo will be in a stronger position when dealing with regulators, healthcare providers, reimbursement framework and key partners. However, expectations should be kept realistic since successful enrollment does not prove clinical effectiveness.